Cabozantinib-associated therapy-refractory lower-leg ulcers in metastatic renal cell carcinoma
Zhide Meng, Tobias M Franz, Benedikt Hindelang, Susanne A Steimle-Grauer, Tilo Biedermann · 2026
Read Cabozantinib-associated therapy-refractory lower-leg ulcers in metastatic renal cell carcinoma by Zhide Meng, Tobias M Franz, Benedikt Hindelang, Susanne A Steimle-Grauer, Tilo Biedermann (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13527509.txt.
Description
Meng and colleagues reported a 2026 case of stubborn lower-leg ulcers linked to cabozantinib, in a man with kidney cancer that had spread widely. Cabozantinib is a targeted cancer drug that blocks blood vessel growth signals. His cancer had first been treated with immunotherapy, stopped for a severe skin reaction, and he switched to cabozantinib in 2022 after radiation failed, with a good tumor response.
Meng describes how a small spontaneous ulcer appeared on his right leg about six months into cabozantinib treatment, on a background of untreated poor vein circulation. It worsened into a painful, treatment-resistant wound by mid-2024. The drug was paused on suspicion of toxicity, swabs found only normal skin bacteria. A biopsy showed an inflammation pattern resembling pyoderma gangrenosum, an ulcer disease driven by immune cells. The authors discuss how vessel-blocking drugs impair wound healing and outline management lessons for similar patients.
Catalog record
| CREATOR | Zhide Meng, Tobias M Franz, Benedikt Hindelang, Susanne A Steimle-Grauer, Tilo Biedermann |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |